Associated Banc-Corp’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.34M Sell
55,053
-1,857
-3% -$108K 0.09% 134
2025
Q4
$3.07M Sell
56,910
-21,360
-27% -$1.03M 0.08% 139
2025
Q3
$3.53M Sell
78,270
-7,893
-9% -$369K 0.09% 135
2025
Q2
$3.99M Sell
86,163
-21,889
-20% -$1.07M 0.11% 132
2025
Q1
$6.59M Sell
108,052
-28,425
-21% -$1.66M 0.2% 101
2024
Q4
$7.72M Sell
136,477
-12,307
-8% -$688K 0.23% 91
2024
Q3
$7.7M Sell
148,784
-14,083
-9% -$661K 0.23% 96
2024
Q2
$6.76M Sell
162,867
-7,239
-4% -$324K 0.21% 100
2024
Q1
$9.22M Sell
170,106
-7,741
-4% -$394K 0.29% 84
2023
Q4
$9.13M Sell
177,847
-11,392
-6% -$598K 0.32% 84
2023
Q3
$11M Buy
189,239
+909
+0.5% +$55.7K 0.43% 65
2023
Q2
$12M Sell
188,330
-1,016
-0.5% -$68.1K 0.46% 65
2023
Q1
$13.1M Sell
189,346
-6
-0% -$423 0.53% 62
2022
Q4
$13.6M Buy
189,352
+1,643
+0.9% +$124K 0.57% 59
2022
Q3
$13.3M Sell
187,709
-2,149
-1% -$156K 0.62% 51
2022
Q2
$14.6M Sell
189,858
-7,578
-4% -$577K 0.64% 51
2022
Q1
$14.4M Sell
197,436
-9,588
-5% -$644K 0.56% 59
2021
Q4
$12.9M Sell
207,024
-7,328
-3% -$430K 0.47% 66
2021
Q3
$12.7M Sell
214,352
-9,808
-4% -$646K 0.5% 64
2021
Q2
$15M Buy
224,160
+28,778
+15% +$1.88M 0.59% 54
2021
Q1
$10.9M Sell
195,382
-63,400
-24% -$3.94M 0.68% 50
2020
Q4
$16.1M Buy
258,782
+18,038
+7% +$1.11M 0.63% 50
2020
Q3
$14.5M Sell
240,744
-5,615
-2% -$338K 0.62% 49
2020
Q2
$14.5M Buy
246,359
+33,342
+16% +$1.99M 0.65% 49
2020
Q1
$11.9M Buy
213,017
+21,336
+11% +$1.3M 0.63% 49
2019
Q4
$12.3M Buy
191,681
+28,410
+17% +$1.63M 0.61% 53
2019
Q3
$8.28M Buy
163,271
+3,117
+2% +$146K 0.45% 65
2019
Q2
$7.26M Buy
160,154
+32,453
+25% +$1.51M 0.4% 70
2019
Q1
$6.09M Buy
127,701
+7,617
+6% +$379K 0.35% 79
2018
Q4
$6.24M Sell
120,084
-4,088
-3% -$220K 0.41% 73
2018
Q3
$7.71M Sell
124,172
-1,565
-1% -$92.9K 0.43% 71
2018
Q2
$6.96M Sell
125,737
-2,295
-2% -$124K 0.41% 70
2018
Q1
$8.1M Sell
128,032
-1,756
-1% -$113K 0.46% 62
2017
Q4
$7.95M Sell
129,788
-14,620
-10% -$914K 0.43% 65
2017
Q3
$9.21M Sell
144,408
-6,434
-4% -$376K 0.51% 61
2017
Q2
$8.4M Sell
150,842
-4,449
-3% -$242K 0.48% 62
2017
Q1
$8.44M Sell
155,291
-86,230
-36% -$4.73M 0.5% 60
2016
Q4
$14.1M Sell
241,521
-5,586
-2% -$305K 0.88% 36
2016
Q3
$13.3M Buy
247,107
+8,569
+4% +$550K 0.85% 35
2016
Q2
$17.5M Sell
238,538
-3,920
-2% -$277K 1.13% 24
2016
Q1
$15.5M Buy
242,458
+4,497
+2% +$284K 1.02% 25
2015
Q4
$16.4M Buy
237,961
+1,018
+0.4% +$67.3K 1.08% 24
2015
Q3
$14M Sell
236,943
-8,449
-3% -$536K 0.98% 30
2015
Q2
$16.3M Sell
245,392
-3,583
-1% -$236K 1.05% 26
2015
Q1
$16.1M Buy
248,975
+9,339
+4% +$585K 1.01% 28
2014
Q4
$14.1M Buy
239,636
+48,515
+25% +$2.74M 0.89% 33
2014
Q3
$9.78M Buy
191,121
+62,059
+48% +$3.1M 0.64% 50
2014
Q2
$6.26M Sell
129,062
-5,046
-4% -$249K 0.41% 73
2014
Q1
$6.97M Sell
134,108
-6,414
-5% -$341K 0.48% 60
2013
Q4
$7.47M Sell
140,522
-3,153
-2% -$161K 0.54% 58
2013
Q3
$6.65M Sell
143,675
-3,078
-2% -$135K 0.53% 59
2013
Q2
$6.56M Buy
+146,753
New +$6.37M 0.54% 57

Other funds holding BMY

Associated Banc-Corp's BMY Position: Q1 2026 in Review

Associated Banc-Corp reduced its Bristol-Myers Squibb (BMY) stake by 3.3% in Q1 2026, selling an estimated $108K and leaving 55,053 shares worth $3.34M. The position accounts for 0.09% of the portfolio, ranked #134.

Associated Banc-Corp first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $17.5M in Q2 2016. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Associated Banc-Corp held 55,053 shares of Bristol-Myers Squibb worth $3.34M as of Q1 2026.
  • Associated Banc-Corp sold 1,857 Bristol-Myers Squibb shares in Q1 2026, an estimated $108K.
  • Bristol-Myers Squibb made up 0.09% of Associated Banc-Corp's portfolio in Q1 2026, its #134 holding.
  • Associated Banc-Corp first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
  • Associated Banc-Corp's Bristol-Myers Squibb position peaked at $17.5M in Q2 2016.
  • 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Associated Banc-Corp's 13F filing for Q1 2026, filed 1 May 2026.